Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
CSL Behring to showcase clinical advances and insights in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with Hizentra ® [human normal immunoglobulin, 20%, subcutaneous], at the 2019 Peripheral Nerve Society Annual Meeting | ||
By: PR Newswire Association LLC. - 20 Jun 2019 | Back to overview list |
|
GENOA, Italy, June 20, 2019 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that it will support the presentation of eight scientific posters at the 2019 annual meeting of the Peripheral Nerve Society (PNS), to be held 22-26 June, in Genoa, Italy. Research to be presented includes new insights from the PATH trial extension, including long-term Quality of Life (QoL) and outcomes data analyses, and evaluation of IgG levels as a potential biomarker to predict treatment response in the treatment of CIDP. PATH is the largest clinical trial ever conducted with CIDP patients. An additional CSL Behring-supported presentation will assess the impact of CIDP diagnosis delay (after incident symptoms) on physical function (PF) using self-reported data from the GBS|CIDP Foundation International survey. "PATH study data continues to guide healthcare providers and CIDP researchers in more fully understanding the clinical benefits of subcutaneous Ig treatment, Hizentra, which is already making a difference in helping us fulfill our promise to CIDP patients," said Andrew Koenig, D.O., F.A.C.R., Immunology and Neurology Therapeutic Area Lead, Medical Affairs, CSL Behring. "We are committed to further analysis based on the trial extension results to continue to advance patient care and deliver innovation that will improve quality of life for people living with CIDP." In addition to the meeting presentations, CSL Behring will also host a symposium, "Navigating Diagnosis and Treatment Challenges in CIDP" (23 June, 7 p.m. CET) to review additional insights regarding the diagnosis and treatment of the commonly misdiagnosed condition. David Cornblath, M.D., Professor of Neurology, Johns Hopkins School of Medicine, will chair the discussion which will feature the following lectures: "Impact of over and under diagnosing CIDP," by Jeffrey A. Allen, M.D., Assistant Professor of Neurology, Feinberg School of Medicine, Northwestern University; "Finding the right treatment regimen for CIDP," by Pieter Van Doorn, M.D., Professor of Neuromuscular Disorders. Erasmus MC, University Medical Center, Rotterdam, the Netherlands; and "Optimising CIPD Guidelines," by Peter Van den Bergh, M.D., Director of the Neuromuscular Reference Centre, Cliniques Universitaires St. Luc in Brussels. CSL Behring is the only company to offer a portfolio of biologics to address the unique needs of CIDP patients in several regions around the world – Hizentra®, the first and only subcutaneous immunoglobulin option for CIDP patients, while Privigen® is the first and only 10 percent, ready-to-use, room-temperature stored, liquid intravenous immunoglobulin stabilized with proline. Earlier this year, both Hizentra and Privigen were approved by Japan's Ministry of Health, Labour and Welfare for the treatment of patients with CIDP. About CIDP About Hizentra® About Privigen® About CSL Behring CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX: CSL; USOTC: CSLLY), headquartered in Melbourne, Australia, employs more than 22,000 people, and delivers its life-saving therapies to people in more than 60 countries. For inspiring stories about the promise of biotechnology, visit Vita at CSLBehring.com/Vita and follow us on Twitter.com/CSLBehring. ___________________________ SOURCE CSL Behring |
||
|
||
Copyright 2019 PR Newswire Association LLC. | Back to overview list |